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The renal nerves in chronic heart
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Alicia M. Schiller *, Peter R. Pellegrino and Irving H. Zucker
Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, USA
The function of the renal nerves has been an area of scientific and medical interest for
many years. The recent advent of a minimally invasive catheter-based method of renal
denervation has renewed excitement in understanding the afferent and efferent actions of
the renal nerves in multiple diseases. While hypertension has been the focus of much this
work, less attention has been given to the role of the renal nerves in the development
of chronic heart failure (CHF). Recent studies from our laboratory and those of others
implicate an essential role for the renal nerves in the development and progression of
CHF. Using a rabbit tachycardia model of CHF and surgical unilateral renal denervation,
we provide evidence for both renal efferent and afferent mechanisms in the pathogenesis
of CHF. Renal denervation prevented the decrease in renal blood flow observed in CHF
while also preventing increases in Angiotensin-II receptor protein in the microvasculature
of the renal cortex. Renal denervation in CHF also reduced physiological markers of
autonomic dysfunction including an improvement in arterial baroreflex function, heart rate
variability, and decreased resting cardiac sympathetic tone. Taken together, the renal
sympathetic nerves are necessary in the pathogenesis of CHF via both efferent and
afferent mechanisms. Additional investigation is warranted to fully understand the role
of these nerves and their role as a therapeutic target in CHF.
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Introduction
Chronic heart failure (CHF) is a diverse clinical syndrome in which impairments of ventricular
filling or emptying compromise the ability of the heart to match cardiac output to metabolic
demand. This activates multiple maladaptive mechanisms such as inflammation, oxidative stress,
the renin-angiotensin system (RAS), and the sympathetic nervous system (SNS), which over time
contribute to disease progression (Felder et al., 2003; Tsutsui et al., 2011; Gullestad et al., 2012).
Demographics of CHF
In the United States, approximately six million adults are living with CHF, a number that
is expected to increase to over eight million in the next 15 years (Heidenreich et al., 2013).
These patients suffer from dyspnea, fatigue, exercise intolerance, and edema, which degrade their
quality of life and lead to frequent and costly hospitalizations. The American financial burden
of CHF in 2012 was approximately $31 billion and is projected to balloon to nearly $70 billion
by 2030 (Heidenreich et al., 2013). The prognosis of CHF is poor, with a 5-year mortality of
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approximately 50% (Roger et al., 2004), emphasizing the need for
new therapeutic strategies.
Cardiorenal Interactions in CHF
Cardiac and renal dysfunction are inextricably intertwined in
CHF, evidenced by the fact that over 80% of patients have
renal insufficiency (McAlister et al., 2004). The hemodynamic
disturbances of CHF lead to decreased renal blood flow with
progressive proteinuria, diminished glomerular filtration rate,
and renal fibrosis. Clinical studies have delineated an important
relationship between markers of systemic venous congestion and
renal function that is independent of other common prognostic
markers (Mullens et al., 2008, 2009). Moreover, therapies that
improve cardiac function, like cardiac resynchronization and left
ventricular assist devices (LVAD), also improve renal function in
CHF patients (Boerrigter et al., 2008; Sandner et al., 2009).
Several pieces of evidence implicate the kidney in the
pathogenesis of CHF. Hypertension precedes 75% of incident
CHF cases (Lloyd-Jones et al., 2002), and higher urinary albumin-
to-creatinine ratios (Velagaleti et al., 2010) and hematocrit
levels (Coglianese et al., 2012) are significant risk factors
for the development of CHF. In established CHF, decreased
glomerular filtration and increased renal sodium retention
worsens the volume load on the already failing heart. In fact, renal
dysfunction is a stronger predictor of mortality than New York
Heart Association (NYHA) Functional Class and left ventricular
ejection fraction (LVEF) in CHF patients (Hillege et al., 2000).
The renal contribution to heart failure is further highlighted by a
study of CHF patients on dialysis in whom renal transplantation
improved LVEF from 32% pre-transplant to 52% 12months post-
transplant, normalizing cardiac function in nearly 70% of the
cohort (Wali et al., 2005).
Despite the importance of hemodynamic dysregulation in
CHF, the notion of heart failure as a purely hemodynamic
disorder with purely hemodynamic cardiorenal interactions has
been discredited (Bongartz et al., 2005; Bock and Gottlieb, 2010).
Maladaptive mechanisms, including inflammation, oxidative
stress, RAS activation, and sympatho-excitation, also drive
morbidity and mortality in CHF patients.
The Sympathetic Nervous System in
Chronic Heart Failure
Sympatho-excitation is a major component of the pathological
relationship between the kidney and heart in CHF. The arterial
baroreflex, chemoreflex, cardiac sympathetic afferent reflex,
exercise pressor reflex, and cardiopulmonary reflexes modulate
sympathetic outflow, and all of these reflexes are aberrant
in CHF (Zucker et al., 1995). Sympatho-excitation activates
the RAS and the immune system which increase sympatho-
excitation in a deleterious feed forward fashion (Testa et al.,
1996; Tsutsui et al., 2011; Sousa-Pinto et al., 2014). CHF
is characterized by global sympatho-excitation, with cardiac
and renal sympathetic outflows being particularly increased
(Hasking et al., 1986), thus further implicating the SNS as
an important mediator of deleterious cardiorenal interactions.
Clinical evidence has demonstrated correlations between cardiac
and renal sympathetic efferent activity and mortality in CHF
(Brunner-La Rocca et al., 2001; Ogita, 2001; Petersson et al.,
2005). A new minimally invasive therapeutic strategy targeting
the renal sympathetic innervation has renewed interest in the role
of the afferent and efferent renal nerves in health and disease.
Rabbit Tachycardia Model as a Model for
Human CHF
Recent studies from our laboratory investigated the role of
the renal nerves in CHF in the rabbit rapid ventricular
pacing model (Clayton et al., 2011; Schiller et al., 2013). The
animals were chronically instrumented with ventricular pacing
leads, arterial pressure radiotelemetries, and renal flow probes
(Figure 1A). The kidney instrumented with a flow probe either
underwent surgical denervation (DNV) or remained innervated
(INV). CHF was induced over several weeks and validated
by echocardiography. This model exhibits increases in renal
sympathetic nerve activity (RSNA), plasma angiotensin II, and
plasma norepinephrine (Mousa et al., 2008; Schiller et al., 2013),
recapitulating the pathophysiology of human CHF. All studies
were performed in the conscious state in rabbits that were well
acclimated to the experimental procedures and environment.
Efferent Renal Sympathetic Nerve Activity
in CHF
The kidney receives rich sympathetic efferent innervation of
many structures (Barajas et al., 1992). These renal sympathetic
efferents mediate renal vasoconstriction, sodium reabsorption,
and renin release.
Several studies indicate that the efferent renal nerves are
essential to the renal hypoperfusion in CHF. Figure 1B shows
the effect of renal denervation on renal blood flow (RBF) in our
rabbit model of CHF. CHF significantly reduces RBF to INV
but not DNV kidneys by increasing renal vascular resistance.
These data support the necessity of the renal nerves in the
development of renal hypoperfusion in CHF. Taken with the
observation that acute renal denervation of anesthetized rats
significantly increases RBF in CHF but not control rats (Kon
et al., 1985; DiBona and Sawin, 2004), it seems the renal nerves
exert a tonic vasoconstrictive action in CHF. Importantly, Kon
et al. also found that acute renal denervation increases glomerular
filtration rate while reducing glomerular capillary pressure in
CHF, providing evidence that the elevated efferent RSNA in CHF
impairs renal function.
Several studies have examined the contribution of the renal
nerves to volume dysregulation in CHF. Renal denervation
does not affect sodium excretion or balance in CHF animals
unless they are challenged, for example by sodium restriction
(DiBona and Sawin, 1991) or volume or salt loading (DiBona
et al., 1988; Villarreal et al., 1994; Souza et al., 2004). Regardless
of the challenge, denervated animals with CHF excrete more
sodium than their innervated counterparts. A recent rodent study
Frontiers in Physiology | www.frontiersin.org 2 August 2015 | Volume 6 | Article 224
Schiller et al. The renal nerves in heart failure
FIGURE 1 | Efferent and afferent signaling in the development of
experimental CHF. Rabbits were chronically instrumented with ventricular
pacing leads, arterial pressure radiotelemeters, and renal flow probes, and
underwent surgical denervation or a sham procedure (A). Induction of CHF
by ventricular pacing reduced blood flow in innervated (INV) rabbits but not in
denervated (DNV) rabbits (B). Modified from Clayton et al. (2011). Induction of
CHF also reduced baroreflex gain and potentiated the heart rate response to
metoprolol in INV but not DNV rabbits (C). Modified from Schiller et al. (2013).
suggests that this is because the increased efferent RSNA in CHF
increases Na+-K+-2Cl− co-transporter expression in the thick
ascending limb (Torp et al., 2012).
One study has shown that renal denervation attenuates but
does not normalize the increased plasma renin activity in
experimental CHF (Witty et al., 1972), indicating that the renal
nerves are partly responsible for the maladaptive activation of the
systemic RAS. In summary, efferent RSNA may contribute to the
renal hypoperfusion, volume dysregulation, and RAS activation
in CHF.
Afferent Renal Sympathetic Nerve Activity
in CHF
The kidney is heavily innervated with sensory nerves that
transmit information from the renal chemo- and mechano-
sensitive receptors that monitor parameters including
composition of the interstitial fluid and hydrostatic pressure
changes (Nijima, 1971; Uchida et al., 1971; Recordati et al., 1981).
Activation of the renal afferent nerves modulates hypothalamic
activity, pain sensation, and sympathetic outflow to multiple
organs, including the heart and kidney (Stella and Zanchetti,
1991; Xu et al., 2015). While much of the attention on therapeutic
renal denervation has focused on the role of efferent renal nerves
in cardiovascular disease, renal denervation was first used
clinically to eliminate renal afferent signaling to alleviate kidney
pain (Oldham, 1950). Evidence of the importance of renal
afferent signaling in hypertensive patients has brought more
focus to this limb of the renal nerves in other cardiovascular
diseases (Hering et al., 2013).
Given the ability of the afferent renal nerves to modulate
central reflexes and sympathetic outflow, we investigated the
effects of renal denervation on common markers of autonomic
dysfunction in the rabbit pacing model of CHF (Schiller
et al., 2013). Rabbits were administered an intravenous bolus
of metoprolol, which results in a decrease in heart rate that
is proportional to the resting cardiac sympathetic tone. The
response to metoprolol was greater for CHF-INV rabbits than
healthy rabbits, consistent with elevated cardiac sympathetic tone
in CHF, while CHF-DNV rabbits had a significantly attenuated
metoprolol response compared to CHF-INV rabbits (Figure 1C).
This indicates that the renal nerves play a role in the development
of the cardiac sympatho-excitation in CHF, most likely due to
increased renal afferent feedback.
In the same rabbits, cardiac baroreflex control was assessed
by infusion of vasoactive drugs. CHF-INV rabbits exhibited
decreased baroreflex gain, which was prevented in CHF-
DNV rabbits (Figure 1C). These data indicate that renal
afferent signaling is important in the development of baroreflex
dysfunction in CHF. Additionally, CHF-DNV rabbits had
improved heart rate variability compared to CHF-INV rabbits,
further implicating the renal nerves in the development of
cardiac autonomic dysfunction in CHF. Cardiac sympathetic
tone, and baroreflex sensitivity, and heart rate variability are
prognostic for risk of sudden cardiac death in CHF. Another
study in anesthetized pigs found that renal denervation decreased
ventricular arrhythmias in response to acute ventricular ischemia
(Linz et al., 2013), bolstering the idea that renal afferent signaling
may be pro-arrhythmogenic in CHF. Cumulatively, these data
suggest that the renal sympathetic afferents play a role in the
development of autonomic dysfunction and possibly sudden
cardiac death in CHF.
A recent study employed catheter-based renal denervation
after the development of CHF in sheep (Booth et al., 2015b).
Despite convincing evidence of complete functional afferent and
efferent renal denervation as well as a drop in blood pressure,
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renal denervation did not decrease cardiac sympathetic tone or
improve cardiac baroreflex gain in CHF sheep. The findings
of this study contrast from our own data, but many possible
explanations for these differences exist. First, the experiments
are performed the day after denervation whereas ours were
performed several weeks after denervation, and the short-term
effects of nerve ablationmay bemarkedly different from the long-
term effects as time is required for neural circuit reorganization
and renal and systemic molecular changes. Second, the ovine
CHF model does not exhibit increased RSNA, and renal afferent
signaling may not be important for autonomic dysfunction in
this model. Along these lines, model-specific contributions of the
renal afferents to hypertension has been recently demonstrated
(Foss et al., 2015). Finally, because renal denervation was
performed after induction of CHF, this study raises the very
real possibility that renal afferent nerves are necessary for the
development of autonomic dysfunction in CHF but do not
maintain the autonomic dysfunction in established CHF. The
reconciliation of this study with our own has important bearing
on the viability of the renal nerves as a therapeutic target in CHF.
Renal Sympathetic Nerves and
Neurohumoral Activation in CHF
Evidence from our studies also indicates that the renal nerves
play an important role in the neurohumoral activation of
CHF mediated by both efferent and afferent mechanisms.
CHF-INV rabbits had increased plasma norepinephrine which
was normalized in CHF-DNV rabbits (Schiller et al., 2013).
Furthermore, our laboratory has shown that renal denervation
prevents deleterious molecular changes in the renal cortical
microvasculature, which may be influenced by both local and
circulating factors. Specifically, CHF-INV rabbits exhibited
increased expression of the vasoconstrictive, profibrotic
Angiotensin-II Type 1 Receptor (AT1R) compared to healthy
rabbits (Clayton et al., 2011) while CHF-DNV rabbits did not
show an increase in AT1R protein. Of note, this model, like
human CHF, exhibits increases in circulating Angiotensin-II,
which can, in turn, upregulate the deleterious AT1R in a
feed-forward manner (Zucker et al., 2001). Whether these
changes are a local phenomenon or if similar effects can be seen
throughout the vasculature of denervated animals awaits further
investigation.
Renal Sympathetic Nerves and Cardiac
Function in CHF
In our rapid ventricular pacing model of CHF, the degree of heart
failure is verified by echocardiography, and rabbits are defined
to be in CHF after their LVEF falls below a threshold. Thus,
cardiac function is a controlled parameter, and our studies are
unable to answer questions about the role of the renal nerves
in the development of cardiac dysfunction. However, in a rat
myocardial infarction CHF model, chronic renal denervation
decreased left ventricular end-diastolic diameter and increased
left ventricular fractional shortening (Nozawa et al., 2002),
indicating that the renal nerves play a role in the development
of cardiac dysfunction in this model suggesting that they are
important in the feed-forward pathophysiology of CHF.
The Renal Nerves as a Therapeutic Target
in CHF
Taken together, the above studies implicate both the afferent and
efferent renal nerves in the development of the pathophysiology
of CHF. Despite importance of the renal nerves in the
development of CHF, several open questions remain about their
potential as a therapeutic target. Specifically, the efficacy and
longevity of catheter-based renal denervation and the role of the
renal nerves in established CHF are points of further discussion.
Catheter-based Renal Denervation
In most pre-clinical studies, renal denervation is performed
surgically by stripping the neural tissue from the renal artery
(Clayton et al., 2011; Schiller et al., 2013). The result is essentially
complete denervation, evidenced by nearly 100% reductions
in renal cortical norepinephrine levels in the rabbit, dog,
and rat (Lohmeier et al., 2007; Clayton et al., 2011; Schiller
et al., 2013; Linz et al., 2015). This contrasts from the partial
denervation achieved by bilateral radiofrequency ablation with a
catheter which is performed in patients. The only clinical study
that has directly addressed the efficacy of catheter-based renal
denervation was performed on 10 patients who underwent renal
denervation with the Medtronic Symplicity™ catheter in whom
renal norepinephrine spillover was assessed before and 15–30
days after denervation (Krum et al., 2009). After denervation,
renal norepinephrine spillover was reduced by an average of 47%,
but this response was highly variable between subjects. Much
better results have been achieved in both sheep and pigs (Booth
et al., 2015b), but the fact that the renal nerves do not form
a network around the main renal artery in man may render
such complete denervation impossible (Oldham, 1950). The
partial efficacy of catheter-based techniques in patients contrasts
from surgical denervation, which consistently and completely
eliminates renal norepinephrine in all species. As it stands, it
appears that partial denervation is the best that can be achieved
by catheter-based renal ablation in humans, but this may be
sufficient for a therapeutic benefit, as evidenced by our studies
of unilateral denervation.
In addition to concerns about the completeness of catheter-
based renal denervation, the duration of denervation in patients
remains unknown. The longevity of afferent and efferent
denervation after both surgical and catheter-based denervation
of animals is only a few months (Mulder et al., 2013; Booth
et al., 2015a). In renal transplant patients, histochemical studies
have shown abundant allograft innervation at 8 months post-
transplant (Gazdar and Dammin, 1970), but this innervation
may not be functional even years after transplantation (Hansen
et al., 1994). The time course of both molecular and functional
renal reinnervation after catheter-based denervation remains to
be investigated and will certainly impact the therapeutic potential
of this technique.
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The Renal Nerves in Established CHF
A very important point that our studies were not designed
to address is whether or not the renal nerves remain a
therapeutic target in established CHF. We performed surgical
renal denervation prior to ventricular pacing, and thus the
findings in our studies represent the cumulative contribution
of the renal nerves through the development of CHF. This
does not necessarily mean that the renal nerves actively drive
these same processes in established CHF, a distinction which
is emphasized by studies in other disease models in which
renal denervation is preventative but not therapeutic (Stella
and Zanchetti, 1991; Kim and Padanilam, 2013) and has been
suggested by the aforementioned short-term study in sheep with
CHF (Booth et al., 2015b). Whether or not renal denervation
performed after the development of CHF can slow or reverse the
renal hypoperfusion, autonomic imbalance, and neurohumoral
activation in CHF remains an open question.
Clinical Studies of Renal Denervation in
CHF
The excitement surrounding the Medtronic Symplicity renal
nerve ablation catheter in the wake of promising Phase 1
and 2 clinical trials in hypertension gave way to despair
after the Phase 3 SYMPLICITY HTN-3 failed to achieve its
efficacy endpoints (Bhatt et al., 2014). The reasons for the
disparities between the earlier trials and SYMPLICITY HTN-
3 have been discussed at length by many other authors (Esler,
2014; Kandzari et al., 2015), and include completeness of
denervation, patient selection, the placebo effect, and in-trial
medication regimen changes (Bhatt and Bakris, 2014). Recently,
DENERHTN, which was not sham-controlled but was carried out
at select hypertension centers by experienced interventionalists
in patients on a carefully controlled medication regimen, showed
that the addition of renal denervation to a standard medication
regimen significantly decreased 24-h ambulatory systolic blood
pressure (Azizi et al., 2015). Despite questions about its efficacy,
catheter-based denervation is generally safe. HTN-3 showed that
denervation was no worse than renal angiography in terms of
renovascular complications, renal function, all-cause mortality,
and cardiovascular events, while two patients in DENERHTN
experienced lumbar pain and one developed a groin hematoma.
Presently, ClinicalTrials.gov lists 18 studies for renal
denervation in CHF. Only one, a small pilot safety study in seven
CHF patients, has been completed (Davies et al., 2013). These
patients did not have hypotensive complications or deterioration
of renal function after renal denervation with the Medtronic
Symplicity™ catheter. All patients felt better after denervation
and improved their 6-min walk distance despite no change in
echocardiographic parameters. Many of the other studies are
aimed at particular CHF subgroups, including heart failure with
preserved ejection fraction, CHF with renal impairment, and
CHF secondary to Chagas disease. Also notable is that some of
these trials were withdrawn or terminated following the efficacy
shortcomings of SYMPLICITY HTN-3.
FIGURE 2 | Role of efferent and afferent renal nerves in CHF. Efferent
renal signaling decreases renal blood flow and contributes to volume
dysregulation. Afferent renal signaling contributes to cardiac
sympatho-excitation, baroreflex dysfunction, and arrhythmogenesis.
Conclusion
We have reviewed evidence which implicates both the efferent
and afferent renal sympathetic nerves in the development
several of the pathophysiological hallmarks of CHF, including
renal hypoperfusion, volume dysregulation, cardiac sympatho-
excitation, baroreflex dysfunction, arrhythmogenesis, and
neurohumoral activation (Figure 2). More research, both basic
and clinical, is necessary to determine if and exactly how renal
denervation can be employed as an effective therapeutic strategy
for CHF patients.
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